Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 138.28% | 117.57% | 103.20% | 93.29% | 69.07% |
| Total Depreciation and Amortization | -58.11% | -57.97% | -15.07% | 8.97% | 4.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.41% | -39.24% | -32.53% | -26.05% | -32.37% |
| Change in Net Operating Assets | -238.30% | -690.64% | -442.22% | -535.59% | -301.81% |
| Cash from Operations | 25.87% | 26.35% | 54.99% | 63.49% | 64.39% |
| Capital Expenditure | -- | 55.00% | 81.29% | 87.49% | 79.89% |
| Sale of Property, Plant, and Equipment | -- | -- | 1,296.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 93.91% | -16.96% | -101.38% | -92.29% | -92.91% |
| Cash from Investing | 110.44% | -13.88% | -101.13% | -92.32% | -93.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 71.97% | 44.38% | 22.76% | -6.15% | 5.81% |
| Issuance of Common Stock | -72.84% | 366.58% | 353.11% | 330.69% | 1,864.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | 93.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.71% | -170.80% | -96.76% | -200.13% | 46.15% |
| Cash from Financing | -72.85% | -74.19% | 101.10% | 34.63% | 2,849.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,958.45% | -122.80% | 0.19% | -55.60% | 98.79% |